Enovis Corporation

ENOV Healthcare Medical Devices

Enovis Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 6.66% from fiscal 2024. In the quarter to June 2026, revenue grew 3.23%, EPS grew 96.9%, free cash flow grew 815.8% and total debt fell 7.82%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

19.59 0.24 +1.24%
Market cap
$1.1B
P/E
0.0×
Fwd P/E
195×
Dividend yield
—
F-score
4/9
Altman Z
−0.34
Beneish M
−4.29
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
0.78 0.68 0.57 0.52
P/FCF ratio
76.19 76.33 36.30 18.73
P/Operating CF
21.01 17.17 54.44 15.89
P/B ratio
0.86 1.02 0.88 0.81
EV/Sales
1.37 1.24 1.14 1.07
EV/EBITDA
15.02 12.65 9.44 7.98
EV/FCF
134.43 139.62 72.29 38.71
Current Ratio
2.22 2.02 2.04 1.98
Net Debt/EBITDA
20.61 16.55 16.18 14.38
Debt/Equity
0.67 0.87 0.90 0.87
Earnings Yield
(77.98%) (77.74%) (87.38%) (93.04%)
Free Cash Flow Yield
1.31% 1.31% 2.76% 5.34%
Free Cash Flow per Share
0.51 0.57 (0.50) 0.54
Book value per Share
35.40 26.14 25.81 25.68
Free Cash Flow
29.09 32.29 (28.85) 31.14
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates